In the present study, we have isolated and sequenced the complementary DNAs of two mutant alleles for lysyl hydroxylase (LH) in fibroblasts from one patient (AT750) with EhlersDanlos syndrome type VI (EDS VI). We have identified a putative mutation in each allele which may be responsible for the patient's decreased LH (normalized to prolyl hydroxylase) activity (24% of normal). Intermediate levels of LH activity were measured in the patient's parents, who are clinically normal (father 52%; mother 86%). After the cloning of cDNAs and amplification by PCR, sequence analysis revealed two equally distributed populations of cDNAs for LH in the AT750 cell line. Each allele revealed different but significant changes from the normal sequence. In one allele (allele 1), the most striking change was a triple base deletion that would result in the loss of residue Glu532. The most significant difference in the other allele (allele 2) was a G -A change which would produce a Gly678 -> Arg codon change in a highly conserved region of the enzyme. Restriction analysis identified that allele 1 was inherited from the proband's mother and allele 2 from the father. This study represents the first example of compound heterozygosity for the LH gene in an EDS VI patient, and it appears that there is an additive effect of each mutant allele on clinical expression in this patient. (J. Clin. Invest. 1994.
Introduction
Lysyl hydroxylase (LH)' is a procollagen post-translational modifying enzyme that hydroxylates lysine residues at the Y position ofGly-X-Y peptide sequences ( 1 ). Hydroxylysine residues provide sites for intermolecular covalent crosslinks that are critical for the tensile strength of collagen fibrils (2) . The hydroxylated lysine residues are also sites of attachment for galactosyl and glucogalactosyl side chains; the functions of these carbohydrate modifications are unclear although they may be important in the regulation of crosslink formation and 1 . Abbreviations used in this paper: EDS VI, Ehlers-Danlos syndrome type VI; LH, lysyl hydroxylase; nt, nucleotide(s); PH, prolyl hydroxylase; RT, reverse transcriptase fibrillogenesis (3) . LH exists as a homodimer (a2) of 85,000-mol wt subunits, and requires a-ketoglutarate, Fe2+, ascorbate, and 02 as cofactors ( 1, 4, 5) . The importance ofthis enzyme is demonstrated in patients diagnosed with Ehlers-Danlos syndrome type VI (EDS VI) (6) (7) (8) . Owing to a deficiency of LH activity, these patients exhibit signs of collagen pathology that include neonatal onset ofkyphoscoliosis, joint laxity, and muscle hypotonia. Other manifestations consist of skin hyperextensibility, easy bruisability, and ocular fragility (9, 10) . The potential lethality ofthe disease is a reported tendency for spontaneous arterial rupture (10) . Clinical diagnosis of EDS VI is confirmed by an assay of LH activity in cultured skin fibroblasts (11) .
The genomic sequence of LH has not yet been determined, but the sequence of a full-length cDNA for LH from human placenta was recently reported ( 12) . We have also sequenced a full-length cDNA for LH from a normal cultured dermal fibroblast cell line GM05659 (13) . These sequences, apart from apparent polymorphisms, appear to have identical coding regions and provide a basis for mutational analysis in the LH cDNA from patients with EDS VI. Clinical and biochemical evidence suggest heterogeneity at the LH locus in producing EDS VI (14) (15) (16) . Recent studies confirm this at the molecular level with two reported cases ofdifferent homozygous recessive mutations in LH cDNA, each in two siblings with EDS VI; these include a premature termination codon ( 17) and an 800-bp duplication ( 1 8) , which may be responsible for the disease. Analysis of the location of the different types of mutations responsible for LH deficiency in the LH cDNA will also help to characterize the functional domains of the enzyme's primary structure. In the present study, we report the cloning and sequencing of full-length cDNAs (3 kb) for LH isolated from cultured dermal fibroblasts from a third patient with EDS VI (AT750). We have identified two novel mutant alleles for LH, which indicates that the patient is a compound heterozygote for EDS VI. The parental origin of each mutation correlates with partially reduced LH activity in their fibroblast strains and has confirmed the heterozygosity of the mutation. This represents the first reported example ofcompound heterozygosity in the LH gene, and it appears that a significant mutation in each allele contributes to this patient's disease phenotype.
Patient summary Detailed clinical information on the proband (AT750), up to the age of 6 yr, has been reported ( 19, 20 ( 15, 16, 19, 20) . At The diagnosis of EDS VI was supported by amino acid analysis of his skin which showed zero hydroxylysine per 1,000 residues with normal values being 5 / 1,000. The diagnosis of EDS VI was verified by assay of LH activity from cultured dermal fibroblasts which showed that the patient had a LH/ prolyl hydroxylase (PH) ratio that was 24% of the control values. PH was used as a reference since the activity ofthis enzyme is shown to be normal in EDS VI patients ( 15, 16, 19 ). An autosomal recessive mode ofinheritance was deduced from the same assays performed on his parents' dermal fibroblasts which showed 52% and 86% LH, relative to PH activity, in the father and mother, respectively. Neither parent had clinical evidence for EDS VI. cDNA cloning. PCR products ofdifferent A and B primer combinations were visualized on a 1% agarose-ethidium bromide gel. DNAs of the expected sizes were excised and purified using Magic PCR Preps (Promega Corp., Madison, WI) columns. To create ligatable overhanging ends, the cDNAs, which contained no internal Eco RI sites, were restricted with Eco RI (Promega Corp.) for 3 h, heat-denatured at 70'C for 5 min, and purified using Magic DNA Clean-Up (Promega Corp.) purification columns. Ml13mpl 8 bacteriophage (Eastman Laboratory Research Products, New Haven, CT) was restricted with the same enzyme for 1 h, heat-denatured, phosphatased with calf intestinal phosphatase (Boehringer Mannheim Biochemicals, Indianapolis, IN) for 30 min, heat-denatured, and gel purified. cDNAs and Ml 3mp 18 in the ratio of -2:1 were ligated using T4 DNA Ligase (Promega Corp.) overnight at 16'C. Ligated products were transformed into Escherichia coli strain TG 1 following the method described by Hanahan (22) and incubated overnight on H-top plates. Positive colonies were picked by blue-white selection (23) with further verification by single-stranded sequencing. The number of selected cDNA clones designated as follows, by size and PCR primers, includes three full-length clones of2809 bp (lA-SB) and 10 partial cDNA clones including seven clones of 2,312 bp (2A-SB) and one clone each of 1,775 bp (3A-5B), 1,053 bp ( A-2B), and 514 bp ( lA-IB).
Methods
cDNA subcloning. Owing to the tendency of M 13 phages with inserts larger than -200 nt to give rise to progeny with large-scale deletions (24), the three full-length clones were subcloned into a pFlag (Eastman Laboratory Research Products) multipurpose expression vector. This was performed as previously described using Eco RI to create "sticky ends" in both cDNA insert and pFlag before ligation. Double-stranded cDNAs for the subcloning were generated from plasmid minipreps (Promega Corp.) ofthe three full-length M 13 clones. E. coli strain TG 1 was again used for the transformation, but because no blue-white selection exists for positive pFlag clones, random colonies were picked from overnight culture plates and grown up for isolation by plasmid minipreps. The plasmids were restricted with Eco RI and the positive clones with the correct size inserts (2809 bp) were identified on a 1% agarose-ethidium bromide gel.
DNA sequencing. Single-stranded phagemids for sequencing were prepared from M 13 clones by the standard procedure (23) . Singlestranded phagemids of the pFlag clones were made with the use of helper phage (Eastman Laboratory Research Products) following the supplier's instructions. Sequencing was performed using Sequenase Version 2.0 kit (United States Biochemicals, Cleveland, OH) according to the dideoxy method described by Sanger et al. (25) . The clones were sequenced using a series of synthetic 18-mer primers based on normal LH cDNA sequence (GenBank M98252) and were of the correct strandedness depending on clone orientation. The primers beginningat nt 14 Restriction digests. First-strand cDNA was synthesized from fibroblasts from a normal donor (GM05659), proband (AT750), mother (STI 129), and father (PT1 130). Amplification of the 704-bp region covering both the triplet deletion (nt 1618-1620) observed in allele 1 and the G2056 A change observed in allele 2 was carried out using as 5' primer, the sequence between nt 1498 and 1515, and as 3' primer, the sequence complementary to nt 2185-2202. A similar region was amplified in the individual cDNA clones of alleles 1 and 2. PCR was performed as described and the gel-purified 704-bp fragments were digested at 370 with either Mbo 11 ( 1 h) 
Results
Isolation and sequencing ofLH cDNA clonesfrom A T750. We chose to study the LH cDNA from the AT750 cell line because ofan abnormally sized mRNA identified by Northern blot analysis of LH mRNAs from fibroblasts of 12 EDS VI patients (26) ; hybridization of this blot with a 2.2-kb cDNA probe for LH (21) showed AT750 to have a unique, slightly faster-migrating LH mRNA in the 3.4-kb region compared to control LH mRNA. With the use of RT-PCR techniques, we isolated 10 partial and 3 full-length LH cDNA clones derived from his cultured dermal fibroblasts (AT750). To ensure that any nucleotide differences from our control human LH cDNA sequence did not occur as a result ofTaq polymerase or RT error, the clones were derived from eight different PCR reactions using four different RT-cDNA preparations as templates. Sequence analysis of 13 clones revealed the existence of two distinct populations ofcDNA of almost equal frequency. We designated these two cDNA populations allele 1 (six clones of which two were full-length cDNAs) and allele 2 (seven clones including a third full-length cDNA). It should be noted that polymorphic changes in nucleotide sequence as well as the two mutations described below were specific and distinct between alleles 1 and 2.
Sequence analysis of allele 1. The control LH cDNA sequence codes for a 727-amino acid protein beginning with an 18-amino acid signal peptide. It contains 10 cysteine residues, some of which are thought to be important for Fe2' binding ( 12) . It also contains 4 possible sites for asparagine-linked oligosaccharide attachment ( 12) . These cysteine and asparagine residues were unchanged in allele 1. The most significant change in allele 1 (Fig. 1, boxed) from control LH cDNA is a triplet deletion of bases GAG at nt 1618-1620 that would result in the in-frame loss of residue Glu532 (Fig. 2) . The predicted amino acid loss is positioned 6 amino acids 5' to one of the four asparagine-linked oligosaccharide attachment sites.
Other, presumably less significant, base changes identified in allele 1 (Fig. 1) include a G3,9 --A substitution which would
give an Alagg -* Thr change. This appears to be a polymorphism since the presence of A319 in addition to G319 was observed in LH clones from a normal human placental library ( 17) . In addition, a G382-* T substitution results in a predicted Ala120 Ser amino acid change in allele 1 as well as a conservative A1656 -] C base change.
Sequence analysis ofAllele 2. The most significant difference in the cDNA for allele 2 from control human LH cDNA is a G2056 -A base change (Fig. 1, boxed) that would give a predicted Gly678 --Arg amino acid change (Fig. 2) in a highly conserved region (27) . The mutation is adjacent to a cysteine residue at position 680 and is six amino acids upstream of an asparagine-linked oligosaccharide attachment site. The other two conservative base changes of C318 --T and C1230 T do not produce codon changes and have been previously reported (12, 18) .
Identification ofinheritance ofthe alleles by restriction analyses. Both the deletion ofthe triplet at nt 1618-1620 in allele 1 and the G2056 --A base change in allele 2 create new restriction sites recognized by Mbo II (recognition sequence GAAGA(N)80) and Alw N I (recognition sequence CAG(N)34CTG) respectively (Fig. 3 A) . A 704 bp region between nt 1498 and 2202 covering both sites was amplified by PCR from the cDNAs of a control donor, the proband and his parents, and the cDNA clones from alleles 1 and 2.
As shown in Fig. 3 The amino acid residues predicted from the codons are shown numbered above the line. The solid line represents unchanged DNA sequences and is not drawn to scale. The region between v and v represents the 99% conserved region between amino acid residues 639-715 (27 Fig. 2 . and GAG-deleted nucleotide sequence. A pattern similar to the proband was observed with the cDNA from the proband's mother (lane f), whereas the father's cDNA gave a normal restriction pattern (lane e). In Fig. 3 B( ii), Alw N1 does not cut the 704-bp cDNA fragment from the control allele (lane a) or allele I (lane b), whereas it digests allele 2 into two fragments of 562 and 142 bp (lane c). Digestion of the proband's cDNA gave three fragments of 704, 562, and 142 bp (lane d), confirming that the proband was a heterozygote for the new Alw N 1 restriction site. A similar restriction pattern of the father's cDNA showed the presence ofallele 2 (lane e) which was absent in the mother (lanef). These digests confirm that both abnormal alleles are present in the proband's cDNA and that the proband has inherited allele 1 (E532del) from his mother and allele 2 (G678R) from his father.
Discussion
The biochemical basis for EDS VI was first described in 1972 by Pinnell et al. (6) in which they demonstrated that dermal fibroblasts from patients with EDS VI had decreased LH activity (6) . In the present study, we describe one patient with the clinical features of EDS VI whose cultured skin fibroblasts have only 24% of LH to PH activity compared with that of control ( 19) . Through RT-PCR techniques, we have cloned the cDNAs from the two alleles of LH from this patient and have identified different mutations in each allele that may contribute additively to the patient's clinical phenotype.
We have shown that one allele (allele 1) isolated from this patient's LH cDNA contains a significant triple-nucleotide deletion that would result in the predicted loss of a glutamic acid at residue 532 (E532del). The region in which this triple deletion occurs contains a direct symmetrical repeat of -GAAG- (Fig. 2) , which may predispose this sequence, if it is uninterrupted in the LH gene, to a deletion-type mutation. This has been reported in several other such mutated sequences in which short direct repeats flank a deletion (28) . In allele 1, this deletion would appear to be the major contributor to the patient's disease phenotype; however, as the tertiary structure of LH is not yet known, the precise effect of this deletion on the functional site of the enzyme cannot be presently determined. Other minor base changes identified in allele 1 include a polymorphism and a conservative base change. The significance of the Ala -> Ser codon change is presently unknown. This change has not been observed in sequence analysis of six LH alleles from control fibroblasts ( 13) ; however, it is unlikely to produce a functional change in LH since there is no charge change and this region of the protein is not conserved (27) .
Sequence analysis of the other allele (allele 2) reveals both polymorphic differences from control cDNA and a significant mutation which are not present in allele 1. The most significant mutation in allele 2 is a single-base transition giving rise to a
Gly678
Arg (G678R) (29, 30) . This mutation disrupts a triple glycine peptide sequence in a highly conserved area ofthe primary structure of the enzyme (27) . In this region between amino acids 639 and 715, the polypeptide sequences of chick and human LH are 99% identical. Significantly this highly conserved region of the LH gene containing the mutation appears to encompass the catalytic site of the enzyme (27) . A recent comparison of amino acid sequences of several a-ketoglutarate-coupled dioxygenases, revealed two histidine motifs that are highly conserved (27) laboratory (S. Murad, unpublished observations); a comparison of the LH activities in each parent's fibroblasts with their respective mutations may reflect the degree of the disruption caused by each mutation on the enzyme's functional sites. Our findings suggest that the paternal G678R mutation in the conserved region of LH is more deleterious to enzyme function than the E532del in the maternal allele; however, the structure-function mechanism remains to be determined.
In conclusion, we have found two different mutations for the LH gene in fibroblasts from a patient with EDS VI. This study represents the first example of compound heterozygosity for the LH gene identified in a patient with EDS VI and it would appear that there is an additive effect of each mutant allele on clinical expression in the patient. Determination of the catalytic activity ofthese alleles, expressed individually and together in a system such as baculovirus will enable us to assess the relative effect of each mutation and thus further our understanding of the structural biology of this important enzyme in collagen biosynthesis.
